'Our collaboration with
In July at the 2019 Alzheimer's
'We are encouraged by the preliminary work we have done together and the potential of dantrolene as a first-in-class treatment option for this devastating disease,' said
Eagle's proprietary research continues to yield insights into how dantrolene sodium plays a role in restoring intracellular calcium regulation. Eagle believes that the homeostatic balance of calcium inside cells is essential for the proper function of the nervous system. Eagle's extensive experience with dantrolene suggests that changes in intracellular calcium levels or calcium signaling, which involve complex cellular pathways, may be involved in neurological pathologies and may lead to neurodegeneration and neuron death.
About Alzheimer's disease
About 50 million people have dementia globally, of whom 60 to 70 percent have Alzheimer's disease, according to the
About
Eagle is a pharmaceutical company focused on developing and commercializing innovative and differentiated injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Forward-looking statements are statements that are not historical facts. Words and phrases such as 'anticipated,' 'forward,' 'will,' 'would,' 'may,' 'remain,' 'potential,' 'prepare,' 'expected,' 'believe,' 'plan,' 'near future,' 'belief,' 'guidance,' and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events including, but not limited to: the potential of dantrolene sodium as a treatment for Alzheimer's disease. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle's control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and the Company does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
Contact:
Tel: 212-452-2793
Email: lwilson@insitecony.com
(C) 2020 Electronic News Publishing, source